By Fineline Cube 
China-based Hunan Mabgeek Biotech Co., Ltd has submitted an application to the Hong Kong Stock Exchange to float its shares on the bourse. This move is expected to support the company’s ongoing development and commercialization efforts of innovative biologics targeting allergic and autoimmune diseases, as well as other inflammatory and immune-related disorders.
About Mabgeek Biotech
Founded in 2016, Mabgeek Biotech is a regulatory and clinical stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative biologics. The company has established a robust pipeline of eight innovative drug candidates, all of which are next-generation long-acting antibodies developed through its proprietary technology platforms.
Pipeline Highlights
Mabgeek’s core product, MG-K10, is a potentially best-in-class, self-developed, long-acting anti-IL-4Rα antibody currently at the registration clinical stage. The company is conducting or planning clinical trials for eight indications, including atopic dermatitis and asthma. Other key products in the pipeline include MG-014 and MG-013, further underscoring the company’s commitment to addressing significant unmet medical needs.-Fineline Info & Tech